Elanco Animal Health’s Varenzin-CA1 Receives the US FDA’s Conditionally Approval for Nonregenerative Anemia in Cats with Chronic Kidney Disease
- The US FDA has conditionally approved the first drug, Varenzin-CA1 for the management of nonregenerative anemia in cats with CKD. The US FDA was granted the expanded conditional approval authority in the Animal Drug User Fee Act of 2018 with the program planned to sunset in 2028
- The efficacy of molidustat oral suspension had been established based on the results of a study conducted in 2 phases in 23 cats aged 4-17yrs. from various breeds or breed mixes. Varenzin-CA1 can increase the production of erythropoietin in the kidney & stimulates the bone marrow to produce more red blood cells
- Varenzin-CA1 is in the form of a liquid, administered orally, qd for ~28 days & can be repeated as needed after a minimum of 7-day pause. The drug is only available by prescription from a licensed veterinarian
Ref: pharmacy times | Image: Elanco
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.